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Abstract 
BACKGROUND: The understanding of the etiopathogenesis of gastric carcinoma (GC) can be a base for 
development of new therapeutic methods to reduce mortality and to increase survival in patients with GC. The 
percentage of Epstein - Barr virus (EBV) positive gastric carcinomas is uncertain, and the etiologic importance of 
EBV in the pathogenesis of GC has still not been elucidated. 
AIM: This study aimed to determine the percentage of EBV associated GC as well as to determine their 
clinicopathological characteristics. 
MATERIAL AND METHODS: The study included 80 patients with GC who were analysed for ethnicity, local 
growth of a tumour (T status), the presence of nodal metastases (N), the presence of distant metastases (M), 
stage of the disease and degree of carcinoma differentiation. For detection of EBV, immunostainings were 
performed on tumour tissue and the peripheral non-tumour gastric mucosa. 
RESULTS: Positive immunostaining with an antibody against EBV was found in 19 (23.75%) of the 80 patients 
with gastric carcinomas. EBV immunostainings were significantly different in patients with or without metastasis 
and between patients of Macedonian and Albanian ethnicity (p < 0.0001, p < 0.009, respectively). EBV 
immunoexpression was significantly associated with the presence of distant metastases and with patients of 
Albanian ethnicity. 
CONCLUSION: Association of EBV immunostainings with distant metastasis in patients with GC suggests the 
influence of EBV infection on the progression of gastric carcinoma. Due to scarce and doubtful literature data on 
EBV associated GC, further studies are necessary to determine the role of EBV regarding aetiology, treatment 
and prognosis in patients with EBV associated gastric carcinoma. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
The survival rate of patients with gastric 
carcinoma (GC) is still low in spite of the numerous 
surgical techniques and development of 
supplementary preoperative, neoadjuvant and 
adjuvant protocols for chemotherapy [1] [2] [3] [4]. 
Therefore, medical treatment of gastric carcinoma 
urgently requires new therapeutic options. The 
understanding of the etiopathogenesis of this 
carcinoma can be a solid base for the development of 
new therapeutic methods for decreasing the mortality 
and increasing the survival rate in GC patients. 
Over the last decade, a large number of data 
have been published on the association of gastric 
carcinoma with Epstein - Barr virus (EBV) that is 
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believed to play a role in the carcinogenesis of this 
neoplasm. The percentage of EBV positive gastric 
carcinoma is uncertain, and the etiological importance 
has still not been elucidated [5] [6]. The conducted 
meta-analysis of 70 studies that included a total of 
15,952 cases of GC revealed that EBV positive gastric 
carcinomas differed from the other gastric carcinoma 
by gender distribution, anatomic localisation and 
surgically different anatomy, indicating that EBV-
associated gastric carcinoma is a particular etiological 
entity [5]. Epidemiological studies from different 
regions and studies that contribute to defining the role 
of EBV in the carcinogenesis and progression of GC 
are useful for the development of new therapeutic 
modalities [6]. 
This study aimed to determine the association 
of EBV with gastric carcinoma as well as to correlate it 
with different clinicopathological parameters. 
 
 
 
Material and Methods 
 
This study included 80 patients with gastric 
carcinoma surgically treated at the University Clinic for 
Abdominal Surgery in Skopje, whose operative 
material was analysed at the Institute of Pathology, 
Medical Faculty in Skopje. 
The following parameters were analysed in 
the study: ethnicity of patients, local tumour growth (T 
status), the presence of nodal metastasis (N), the 
presence of distant metastasis (M), stage of the 
disease and degree of carcinoma differentiation. 
The data for the parameters of the TNM 
classification (AJCC Cancer Staging 2017) were 
obtained from the archival histopathological reports of 
the Institute of Pathology in Skopje, and for the clinical 
stage we used patient’s files from the University Clinic 
for Abdominal Surgery in Skopje, including ultrasound 
and computed tomography files.  
For detection of EBV, immunostainings were 
performed on tumour tissue and the peripheral non-
tumour gastric mucosa. 
A standard commercial control was used for 
immunostaining control. 
Immunohistochemical stainings for EBV were 
made with a standard procedure using 
Immunoperoxidase LSAB + system and specific 
primary monoclonal EBV-antibody (DAKO – 
Monoclonal Mouse. Anti-Epstein Barr Virus, LMP. 
Clones CS. 1-4. Code IR753). 
EBV expression was defined in 2 histological 
patterns, nuclear and cytoplasmic (Figure 1). 
 
Figure 1: A) Nuclear positivity for EBV in signet cell gastric 
carcinoma (10 x 20); B) Nuclear EBV positivity in a cluster of glands 
in peri-tumour mucosa with intestinal metaplasia (10 x 10); C) 
Cytoplasmic positivity for EBV in gastric cancer (10 x 20); D) 
Cytoplasmic EBV positivity in peri-tumor cylindrical cells and in 
plasma cells present in submucosa of the gaster (10 x 20) 
 
Descriptive statistical methods were used for 
statistical analysis of the data. Categorical variables 
are presented with absolute and relative numbers (%). 
Fisher’s exact test, Student’s t-test and Chi-square 
test were used for comparison of categorical 
variables. Spearman’s correlation coefficient was 
used to determine the degree of correlation between 
analysed parameters. The statistical program SPSS 
for Windows, version 19.0 was used. 
 
 
Results 
 
Expression of EBV in cells was nuclear and 
cytoplasmic. Nuclear expression was found in 15 
(18.75%) cases and cytoplasmic in 4 (5%) cases. In 
10 (66.66%) of positively stained cases, nuclear EBV 
expression showed the patchy distribution in clusters 
of cells and the other 5 (33.33%) cases EBV positivity 
was diffuse in the tumour cells. The expression of 
EBV in the peri-tumour gastric mucosa showed patchy 
distribution. 
Positive expression of EBV protein was also 
detected in plasma cells present in the tumour stroma, 
or gastric submucosa of the patients with GC (Figure 
1). 
Positive immunostaining with the antibody 
against EBV was found in 19 (23.75%) of the total of 
80 gastric carcinomas. 
The mean age of patients with negative EBV 
expression was 66.05 ± 10.6 years, and of those with 
positive EBV expression was 63.2 ± 9.5 years (p > 
0.05). 
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The immunoexpression of EBV about the 
analysed clinicopathologic parameters is shown in 
Table 1. 
Table 1: Immunoexpression of EBV about the analysed 
clinicopathologic parameters  
Parameter EBV expression 
Gender N EBV - EBV+ P-value 
Male 
Female 
25 
55 
21(84%) 
40 (72.73) 
4 (16) 
15 (27.27) 
0.27 ns 
P (Chi-square test) 
 
Intragastric localisation 
Cardia 
Body 
Pylorus 
31 
20 
29 
23 (74.19) 
14 (70) 
24 (82.76) 
8 (25.81) 
6 (30) 
5 (17.24) 
0.55 ns 
P (Fisher exact 
test) 
 
T  
T1 
T2 
T3 
T4 
4 
13 
14 
49 
4 (100%) 
11 (84.62) 
8 (57.14) 
38 (77.55) 
0 
2 (15.38) 
6 (42.86) 
11 (22.45) 
0.25 ns 
P (Fisher exact 
test) 
 
Lymph node metastasis 
No 
Yes 
16 
64 
12 (75%) 
49(76.56%) 
4 (25%) 
15 (23.44%) 
1.0 Ns 
P (Fisher exact 
test) 
M 
No 
Yes 
72 
8 
53 (73.61) 
0 
19 (26.39) 
8 (100) 
<0.0001 sig 
P (Fisher exact 
test) 
Stage 
I 
II 
III 
IV 
7 
17 
47 
9 
7 (100%) 
11 (64.71) 
34 (72.34) 
9 (100) 
0 
6 (35.29) 
13 (27.66) 
0 
0.076 ns 
P (Fisher exact 
test) 
 
Grade 
G1 
G2 
G3 
1 
36 
43 
0 
30 (83.33) 
31 (72.09) 
1 (100%) 
6 (16.67) 
12 (27.91) 
0.12 ns 
P (Fisher exact 
test) 
Ethnicity     
Macedonian 
Albanian 
62 
18 
52 (83.87) 
9 (50) 
10 (16.13) 
9 (50) 
0.009 sig 
P (Fisher exact 
test) 
 
The results obtained in this study regarding 
positivity of EBV between patients with gastric 
carcinoma with different N stage showed no 
significant difference (p > 0.05). 
A significant difference regarding 
immunoexpression of EBV was found in GC patients 
with or without distant metastases (p < 0.0001). In 
patients with gastric carcinoma, the presence of 
infection along with EBV was significantly associated 
with distant metastases. 
Infection with Epstein-Bar virus was 
significantly more common among patients of 
Albanian nationality than in Macedonian patients (p = 
0.009). EBV immunoexpression was detected in 50% 
(9) of Albanian patients against 16.13% (10) of 
Macedonian patients. 
 
 
Discussion 
 
EBV is a herpes virus that is widely spread 
among the human population. The infection with EBV 
is commonly acquired during early childhood by 
salivary transmission [7]. The virus causes long-term 
infection of B lymphocytes in about 90% of adults, 
who are asymptomatic. A small percentage of infected 
people develop hematopoietic, epithelial and 
mesenchymal tumours. The EBV infection is a cause 
for the development of Burkitt lymphoma, lymphoma 
associated with immunosuppression, Hodgkin's 
lymphoma, sinonasal angiocentric T lymphoma, 
nasopharyngeal carcinoma and leiomyosarcoma in 
immunocompromised patients [5] [7]. It is believed 
that the oncogenic effect of the virus is carried out by 
expression of an EBV nuclear antigen and latent 
membranous proteins that interact with some 
suppressor genes and signal pathways [7].  
According to literature data, the EBV infection 
is associated with 2-16% of gastric carcinoma, but the 
published data, in general, refer to the role of EBV in 
carcinogenesis. Few data on the association of EBV 
with gastric carcinoma and its characteristics are 
available in the literature [7] [8] [9] [10]. The 
prevalence of gastric carcinoma associated with EBV 
infection shows geographic variations [11] and is 
related to the lifestyle of patients. Thus, studies about 
EBV associated gastric carcinomas are necessary 
and very actual [5] [6].  
Gastric carcinomas of the antrum show a low 
percentage of EBV-associated infection compared to 
the carcinoma of the cardia [5], and it is found in the 
highest percentage (90.5%) in lymphoepithelioma-like 
gastric carcinoma [12].  
Some studies have demonstrated the 
association of EBV gastric carcinoma with the age of 
patients [13]. 
The meta-analysis conducted by Lee JH et 
al., of 48 studies on EBV-associated gastric 
carcinoma (EBVaGC) showed a significant 
association with the nationality. The analysis also 
found that EBVaGC was more frequent in men, young 
individuals, Caucasians and Latin Americans, in 
cardia as a localisation of the carcinoma, and in the 
diffuse histological type [14].  
In our study, we detected EBV presence in 
23.75% (19) of our patients, which is a high 
percentage of EBV-associated GC in comparison with 
the results in the literature [11] [13]. EBV 
immunoexpression was significantly different in 
patients with or without metastasis and patients of 
Macedonian and Albanian nationality.  
EBV immunosuppression was significantly 
associated with the presence of distant metastases 
and with Albanian ethnicity. 
The significant correlation of EBV 
immunosuppression with distant metastasis in GC 
patients suggests the influence of EBV infection on 
the progression of gastric carcinoma.  
Due to relatively limited and doubtful literature 
data about EBVaGC, further studies are necessary to 
determine the role of EBV regarding the aetiology, 
treatment and prognosis in patients with EBV 
associated carcinoma.  
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